

TOP

THORACIC
ONCOLOGY
PADOVA



The optimization of histological classification and genomic characterization of Non-Small Cell Lung Cancer (NSCLC), and the implementation of liquid biopsy in molecular assessment and monitoring during treatment, are strictly related to the development of new drugs achieving outcome improvement especially in the metastatic disease. Innovative drugs as tyrosine kinase inhibitors targeting oncogene-addicted tumors and, more recently, PD1/PD-L1 immune checkpoint inhibitors have been quickly translated in the clinical practice, changing the diagnostic-therapeutic algorithm of NSCLC patients. Immune checkpoint inhibitors have been also investigated in locally advanced NSCLC, or in other thoracic cancers such as Small Cell Lung Cancer and Malignant Pleural Mesothelioma. The evolving landscape of the diagnostic and therapeutic pathways in thoracic oncology raised some burning issues.

The importance of an optimal multidisciplinary management will be highlighted during the conference, including but not limited to a central role of thoracic surgeon and pneumologist for adequate tumor samples collection, the interaction with the pathologist and the molecular oncologist for genomic

assays optimization and prioritization, and the increasing role of radiation oncologist in treatment planning of oligoprogression to new anticancer drugs and of locally advanced NSCLC where immunotherapy recently found its place in the consolidation setting.

Another critical issue emerging with the advent of innovative oncology drugs is the need of real-life studies which are an essential element of evidence-based medicine, allowing informed decision-making around the effectiveness and safety of therapies. They can provide information on patients and situations that may be challenging to assess using only data from randomized controlled trials, e.g. treatment adherence and persistence, treatment patterns, guideline adherence, challenging-to-treat populations, drug safety, risk stratification, comparative effectiveness, and cost-effectiveness.

The role of lung units and oncology networks in research promotion, definition of diagnostic-therapeutic pathways and drug recommendations in order to minimize heterogenous affordability, availability and prescriptive appropriateness, will be also discussed during the meeting.

SCIENTIFIC COMMITTEE

Laura Bonanno (Oncologia Medica 2 IOV)

PierFranco Conte (Università di Padova)

Jessica Menis (Università di Padova, Oncologia Medica 2 IOV)

Giulia Pasello (Oncologia Medica 2 IOV)

Francesca Lunardi (Patologia Cardiovascolare, Università di Padova)

Federico Rea (Università di Padova)

Marco Schiavon (Chirurgia Toracica, Università di Padova)

CME

Certificate awarding 10 CME credits will be e-mailed within 90 days after the end of the congress. The following medical sciences have been accredited for this Congress: Biology, Pharmacy, Oncology, Pathology, Respiratory System Disease, and Thoracic Surgery.

SUPPORTED BY AN INDEPENDENT EDUCATIONAL SPONSORSHIP FROM



ORGANIZING
SECRETARIAT



via Pagliari, 4 - 26100 Cremona
tel 0372 23310 fax 0372 569605
info@overgroup.eu www.overgroup.eu



TOP


THORACIC
ONCOLOGY
PADOVA

March 29 - 30, 2019

PADOVA

Aula Nievo, Palazzo del Bo, University of Padova
Via 8 Febbraio, 2 - 35122 Padova

WITH THE PATRONAGE OF



DIAGNOSTIC-THERAPEUTIC PATHWAY
OF NSCLC PATIENTS IN THE ERA OF MOLECULAR
CHARACTERIZATION AND INNOVATIVE DRUGS

FRIDAY 29th, MARCH 2019

10:00 - 10:20

Introduction
Pf. Conte, F. Rea

10:20-10:50

PRESENTER: **F. Rea**
Lecture: the changing role of thoracic surgeon at the time of targeted therapies and immunotherapy
W. Weder

I SECTION

Update on NSCLC in 2018 and perspectives for 2019
CHAIRMEN: **G. Pasello, F. Rea**

10:50 - 11:10

Liquid biopsy in NSCLC: Molecular and functional characterization of CTCs
F. Farace

11:10 - 11:30

Oncogene addicted NSCLC: how to overcome resistance?
S. Novello

11:30 - 11:50

Q&A

11:50 - 12:10

Multidisciplinary management of stage III NSCLC: consolidation and neoadjuvant/adjuvant immunotherapy
N. Reguard

12:10 - 12:30

Discussion

12:30 - 14:00

Lunch

14:00 - 14:30

II SECTION
CHAIRMEN: **J. Menis, M. Sepulcri**

14:30 - 15:30

Clinical case panel discussion

PRESENTER 1: **M. Schiavon**

PRESENTER 2: **S. Pilotto**

PANEL: **F. Calabrese, R. Chiari, S. Novello, L. Spaggiari, S. Ramella, N. Reguart**

15:30 - 15:50

Coffee Break

15:50 - 16:30

PRESENTER: **Pf. Conte**

Lecture: From where we come, to where we are until where we will go in NSCLC treatment
G.V. Scagliotti

III SECTION

Oncology network and diagnostic therapeutic pathways in oncology
CHAIRMEN: **Pf. Conte, F. Rea**

16:30 - 16:45

Epidemiology and risk factors for NSCLC in Italy
Servizio Epidemiologico Regione Veneto

16:45 - 17:00

Oncology network model
Pf. Conte

17:00 - 17:15

Lung unit in the organization of oncology network: pros and cons
L. Hendriks

17:15-17:30

Challenges and opportunity of Real World Datasets
P. Bruzzi

17:30 - 17:45

Diagnostic therapeutic pathways and indicators in Veneto
F. Rea

17:45 - 18:00

Lung Cancer biobank: Padova experience
F. Calabrese

18:00 - 18:30

Round table discussion
AIRTUM
AIOM **S. Gori**
SIAPEC-IAP
AIRO **G. Mandoliti**
SICT

AZIENDA ZERO
AGENAS **A. Ghirardini**
REGIONE VENETO

PANEL: **Pf. Conte, F. Rea, F. Calabrese, R. Chiari**

18:30

Wrap-up

SATURDAY 30th, MARCH 2019

IV SECTION

Update on NSCLC in 2018 and perspectives for 2019
CHAIRMEN: **Pf. Conte, F. Rea**

09:00 - 09:30

How VIII TNM edition affects lung cancer management
R. Rami Porta

09:30 - 09:50

Immunotherapy in NSCLC: how to predict efficacy and safety
A. Ardizzoni

V SECTION

Innovative therapeutic strategies in rare thoracic malignancies
CHAIRMEN: **V. Guarneri, G. Pelosi**

09:50 - 10:05

SCLC and Neuroendocrine tumors
M. Tiseo

10:05 - 10:20

MPM and thymic malignancies
P. Baas

10:20 - 10:40

Discussion

10:40 - 11:00

Coffee break

11:00 - 11:30

PRESENTER: **V. Guarneri**
Lecture: Clinical impact of molecular characterization in lung cancer
J. Remon

VI SECTION

News in translation
CHAIRMEN: **A. Paolo Dei Tos, F. Calabrese**

11:30 - 11:50

How to optimize lung sample handling in the era of theranostic biomarkers
E. Thunnissen

11:50 - 12:10

Next generation sequencing techniques
S. Indraco

12:10 - 12:30

Liquid biopsy: the Veneto program
L. Bonanno

12:30 - 12:50

Discussion

12:50 - 13:00

Conclusion
P.F. Conte, F. Rea

FACULTY

ANDREA ARDIZZONI

University of Bologna

PAUL BAAS

University of Amsterdam

LAURA BONANNO

Istituto Oncologico Veneto Padova

PAOLO BRUZZI

IRCCS AOU San Martino - IST, Genova

FIGIELLA CALABRESE

University of Padova

RITA CHIARI

University of Padova

PIERFRANCO CONTE

University of Padova

ANGELO PAOLO DEI TOS

University of Padova

ALESSANDRO GHIRARDINI

Age.Na.S.

VALENTINA GUARNERI

University of Padova

LIZZA HENDRIKS

Maastricht University Medical Center, Netherlands

FRANCOISE FARACE

CHU de Nice, Nice, France

STEFANIA GORI

A.I.O.M.

STEFANO INDRACCOLO

Istituto Oncologico Veneto Padova

GIOVANNI MANDOLITI

A.I.R.O.

JESSICA MENIS

University of Padova

SILVIA NOVELLO

University of Torino

GIULIA PASELLO

University of Padova

G. PELOSI

University of Milano

SARA PILOTTO

University of Verona

SARA RAMELLA

Campus Biomedico Roma

RAMON RAMI PORTA

Dept of Thoracic Surgery, Hospital Universitari Mutua

Terrassa - University of Barcelona, Barcelona, Spain

FEDERICO REA

University of Padova

NOEMI REGUARD

Clínica de Barcelona, Barcelona

JORDI REMON

Centro Integral Oncología Clara Campal CIOCC

Barcelona - HM Delfos

GIORGIO VITTORIO SCAGLIOTTI

University of Torino

MATTEO SEPULCRI

Istituto Oncologico Veneto IRCCS

MARCO SCHIAVON

University of Padova

LORENZO SPAGGIARI

Istituto Europeo di Oncologia Milano

ERIK THUNNISSEN

Amsterdam University Medical Center

MARCELLO TISEO

University of Parma

WALTER WEDER

University Hospital Zurich, Department of Thoracic Surgery